{"entity":{"id":"pas-004","kind":"drug","name":"PAS-004","aka":[],"tldr":"PAS-004 is an experimental small molecule from Pasithea Therapeutics, in phase 1 trials for MAPK pathway-driven advanced solid tumours and NF1-associated plexiform neurofibromas.","summary":"PAS-004 is a small molecule (oral, macrocyclic) from Pasithea Therapeutics. An oral small-molecule allosteric inhibitor of MEK1 and MEK2 with a macrocyclic structure designed to improve metabolic stability and its pharmacokinetic profile. Its furthest stage is phase 1, for MAPK pathway-driven advanced solid tumours (RAS, NF1 or RAF mutations) and NF1-associated plexiform neurofibromas. ClinicalTrials.gov registers it in 2 studies linked below. Two phase 1 trials recruiting: NCT06299839 (advanced solid tumours with RAS, NF1 or RAF mutations) and NCT06961565 (adults with NF1 plexiform neurofibromas). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Pasithea Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026036434/ea0275535-10k_pasithea.htm"},{"label":"Pasithea Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026036434/ea0275535-10k_pasithea.htm"},{"label":"Pasithea Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06299839"},{"label":"ClinicalTrials.gov: trials of PAS-004","url":"https://clinicaltrials.gov/search?intr=PAS-004"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["mek"],"drugs":[],"companies":["pasithea-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06299839","nct06961565"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PAS-004","modality":"Small molecule (oral, macrocyclic)","mechanism":"An oral small-molecule allosteric inhibitor of MEK1 and MEK2 with a macrocyclic structure designed to improve metabolic stability and its pharmacokinetic profile.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pas-004/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"}],"company":[{"id":"pasithea-therapeutics","kind":"company","name":"Pasithea Therapeutics","route":"/companies/pasithea-therapeutics/"}],"trial":[{"id":"nct06961565","kind":"trial","name":"PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas","route":"/trials/nct06961565/"},{"id":"nct06299839","kind":"trial","name":"PAS-004 in Patients With Advanced Solid Tumors","route":"/trials/nct06299839/"}]}}